Our in vitro benefits counsel that EAM-2201 ought to be examined regarding probable in vivo pharmacokinetic drug–drug interactions due to time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 activities and aggressive inhibition of UGT1A3 action. That is a preview of subscription written content, log in via an establishment to check https://henryq404zpd7.wikiparticularization.com/user